D-129sodium

According to the FDA label: INDICATIONS Constipation, hay fever, rhinitis.

70,872 adverse event reports submitted to the FDA (1998–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with D-129 in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
D-129 adverse event reports by reporter sex
SexReports
Female37,714
Male26,738
Unknown69

By Age Group

View age group data as a table
D-129 adverse event reports by reporter age group
Age groupReports
0-175,352
18-345,717
35-497,921
50-6413,784
65-7410,039
75+7,165

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included D-129. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
D-129 adverse event reports by reported outcome
OutcomeReports
Other Serious36,286
Hospitalization32,196
Non-Serious13,772
Death6,195
Life-Threatening4,803
Disability1,664

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for D-129. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
D-129 adverse event reports by year
YearReports
19981
19991
20011
2004118
2005183
2006273
2007250
2008265
2009415
2010408
2011590
2012855
2013713
20141,175
20152,200
20163,149
20172,534
20183,635
20195,127
20206,421
20215,747
20227,403
20237,787
20249,521
20259,847
2026 (partial)2,253

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with D-129

In FDA adverse event reports that mention D-129, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026